98%
921
2 minutes
20
Regulated hydrolysis of the phosphoinositide phosphatidylinositol(4,5)-bis-phosphate to diacylglycerol and inositol-1,4,5-P defines a major eukaryotic pathway for translation of extracellular cues to intracellular signaling circuits. Members of the lipid-activated protein kinase C isoenzyme family (PKCs) play central roles in this signaling circuit. One of the regulatory mechanisms employed to downregulate stimulated PKC activity is via a proteasome-dependent degradation pathway that is potentiated by peptidyl-prolyl isomerase Pin1. Here, we show that contrary to prevailing models, Pin1 does not regulate conventional PKC isoforms α and βII via a canonical isomerization of the peptidyl-prolyl bond. Rather, Pin1 acts as a PKC binding partner that controls PKC activity via sequestration of the C-terminal tail of the kinase. The high-resolution structure of full-length Pin1 complexed to the C-terminal tail of PKCβII reveals that a novel bivalent interaction mode underlies the non-catalytic mode of Pin1 action. Specifically, Pin1 adopts a conformation in which it uses the WW and PPIase domains to engage two conserved phosphorylated PKC motifs, the turn motif and hydrophobic motif, respectively. Hydrophobic motif is a non-canonical Pin1-interacting element. The structural information combined with the results of extensive binding studies and experiments in cultured cells suggest that non-catalytic mechanisms represent unappreciated modes of Pin1-mediated regulation of AGC kinases and other key enzymes/substrates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11060717 | PMC |
http://dx.doi.org/10.7554/eLife.92884 | DOI Listing |
Int J Mol Med
November 2025
Department of Basic Medical Science, Guangxi Health Science College, Nanning, Guangxi Zhuang Autonomous Region 530023, P.R. China.
Chimeric antigen receptor (CAR) T cell therapy is a type of cellular immunotherapy showing promising clinical effectiveness and high precision. CAR‑T cells express membrane receptors with high specificity, which enable them to identify certain target antigens generated by cancerous cells. The three primary structural elements of the CAR are the extracellular domain, transmembrane domain and cytoplasmic domain.
View Article and Find Full Text PDFbioRxiv
August 2025
Department of Biochemistry, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.
Congenital hyperinsulinism (HI) is a rare genetic disease characterized by overproduction of insulin. One class of potential HI treatments is insulin receptor (IR) antagonists like S961 and Ins-AC-S2, peptides composed of binding segments for each of the IR sites capable of binding insulin: site 1 and site 2. Notably, S597 - containing the same IR binding segments as S961 but in the opposite order (site 2-site 1) - is an IR agonist rather than an antagonist.
View Article and Find Full Text PDFActa Pharm Sin B
August 2025
The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Naval Medical University/Second Military Medical University, Shanghai 200433, China.
Allergic rhinitis (AR), a globally prevalent immune-mediated inflammatory condition, is still an incurable disease. In the present study, we have validated the impact of the Kelch-like ECH associated protein 1 (Keap1)-related oxidative stress and inflammatory response in clinical AR patient peripheral blood and nasal swab samples, emphasizing the biological relevance of Keap1 and AR. Targeting Keap1 -nuclear factor erythroid 2-related factor 2 (Nrf2) related anti-oxidative stress may be effective for AR intervention.
View Article and Find Full Text PDFLife Sci
August 2025
Phase I Clinical Trial Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China. Electronic address:
Aims: This study aimed to overcome the limited protective efficacy of the bivalent DNA vaccine (DNA-OprF/PcrV) against Pseudomonas aeruginosa (PA) infection by developing a complexed adjuvant strategy to enhance immunogenicity and protection, providing a novel clinical candidate vaccine.
Materials And Methods: We formulated a bivalent DNA vaccine encoding PA antigens OprF and PcrV (DNA-OprF/PcrV) complexed with the TLR9 agonist CpG adjuvant (DNA-OprF/PcrV + CpG). In vitro mechanistic studies assessed synergistic pathway activation and dendritic cell maturation, while murine models evaluated humoral immunity (antibody titers), cellular immunity (Th1/CTL responses), and protective efficacy via pulmonary infection models with bacterial burden quantification and inflammation analysis.
Vaccines (Basel)
July 2025
Analytical Sciences Immunology, Sanofi, 1755 Steeles Avenue West, Toronto, ON M2R 3T4, Canada.
Background/objectives: An initial COVID-19 candidate vaccine containing a purified ancestral SARS-CoV-2 spike antigen was characterized with an ELISA using recombinant monoclonal antibodies (mAbs) generated against this variant. Upon the emergence of a new Beta (B.1.
View Article and Find Full Text PDF